Genetics & Breast Cancer
Genetics & Breast Cancer
Advertisement
Dr. Sadie Dobrozsi, EvolentGenetics & Breast Cancer | March 25, 2025
Dr. Sadie Dobrozsi discusses the importance of "pan-cancer" testing, especially as it pertains to breast cancer.
Jordana JampelGenetics & Breast Cancer | March 25, 2025
The most frequent changes detected were additional copies of chromosome 1q and losses of chromosomes 10q, 16q, and 22.
Jordana JampelGenetics & Breast Cancer | March 25, 2025
Heterozygosity in BRCA1 genes is not enough to prevent tumor proliferation, according to researchers out of Harvard.
Jordana JampelGenetics & Breast Cancer | March 25, 2025
Researchers designed a interpretable deep learning model for detecting BRCA pathogenic variants of breast cancer.
Jordana JampelGenetics & Breast Cancer | March 25, 2025
This could be a needed breakthrough for those predisposed to breast and ovarian cancer mutations.
Jordana JampelGenetics & Breast Cancer | March 25, 2025
BUB1 has potential prognostic value in therapy decision-making across breast cancer characterizations.
Dr. Sadie Dobrozsi, EvolentGenetics & Breast Cancer | March 26, 2025
Dr. Sadie Dobrozsi spoke on the importance of genetic testing in breast cancer to better understand the disease.
Rob DillardGenetics & Breast Cancer | March 25, 2025
Researchers identified immune system white blood cells that appear closely related to BC cells that are likely to spread.
Rob DillardGenetics & Breast Cancer | March 25, 2025
Researchers have completed the most extensive mapping of healthy breast tissue cells to date.
Rob DillardGenetics & Breast Cancer | March 25, 2025
Researchers used a global DNA methylation profile to estimate the microenvironment of inflammatory breast cancer.
Rob DillardGenetics & Breast Cancer | March 25, 2025
While half of all carriers of inherited cancer pathogenic variants are men, not enough men undergo genetic testing.
Rob DillardHER2 Breast Cancer | March 25, 2025
Using the HER2DX genomic tool is feasible in a real-world setting of patients with early-stage HER2-positive breast cancer.
Patrick DalyGenetics & Breast Cancer | March 25, 2025
Real-world outcomes were comparable to clinical trials in breast cancers with BRCA mutations treated with PARP inhibitors.
Advertisement